Latest Human Genome Sciences Stories
The FDA has approved Benlysta, making it the first new treatment for lupus to receive the agency's blessing in five decades.
A drug for lupus, produced by Human Genome Sciences Inc, is set to get clearance from health regulators, bringing patients the first approved treatment in more than 50 years, and potentially bringing heavy revenue to the company.
HONG KONG, March 1 /PRNewswire/ - Today, www.WorldStreetFundamentals.com released its industry report highlighting Dendreon Corp. (NASDAQ: DNDN) and Human Genome Sciences, Inc. (NASDAQ: HGSI).
WASHINGTON, Nov. 16, 2010 /PRNewswire-USNewswire/ -- Today the U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee voted overwhelmingly (13 to 2) to recommend BENLYSTAÂ® for approval as a treatment for the autoimmune disease lupus.
WASHINGTON, Oct. 14 /PRNewswire/ -- The newly merged Lupus Foundation of America-DC/MD/VA Chapter (LFA-DC/MD/VA) at http://www.lupusdmv.org will launch wider chapter services in Virginia with the Second Annual Walk for Lupus Now! Richmond on Saturday, Oct. 30 at 3 p.m.
WASHINGTON, May 13 /PRNewswire-USNewswire/ -- More than 600 people turned out tonight for the Lupus Foundation of America's (LFA) National Butterfly Gala, which recognized Ted Turner, Chairman, Turner Enterprises, Inc., Senator, Daniel K.
WASHINGTON, May 10 /PRNewswire/ -- The Lupus Foundation of America Greater Washington Chapter (LFAGW) set a nationwide chapter record for its 4th Annual Walk for Lupus Now! at http://www.dclupuswalk.org Washington, raising more than $250,000 with 2,500 walkers and $270,000 expected by the end of May.
SCOTTSDALE, Ariz., Nov.
BENLYSTA(TM) Successful in Second Pivotal Clinical Trial WASHINGTON, Nov.
Second successful phase III trial points to the first new lupus treatment in over 5O years. NEW YORK, Nov.